• 1
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22(8): 9838.
  • 2
    Stroke Risk in Atrial Fibrilation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007; 69(6): 54654.
  • 3
    Daoud EG, Bogun F, Goyal R, Harvey M, Man KC, Strickberger SA, et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996; 94(7): 16006.
  • 4
    Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339(10): 65966.
  • 5
    Savelieva I, John CA. Atrial fibrillation and heart failure: natural history and pharmacological treatment. Europace 2004; 5(Suppl. 1): S519.
  • 6
    Tsang TS, Gersh BJ, Appleton CP, Tajik AJ, Barnes ME, Bailey KR, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002; 40(9): 163644.
  • 7
    Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009; 373(9658): 15566.
  • 8
    Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation. J Am Coll Cardiol 2012; 60(22): 226370.
  • 9
    Rudolph V, Andrie RP, Rudolph TK, Friedrichs K, Klinke A, Hirsch-Hoffmann B, et al. Myeloperoxidase acts as a profibrotic mediator of atrial fibrillation. Nat Med 2010; 16(4): 4704.
  • 10
    Li J, Solus J, Chen Q, Rho YH, Milne G, Stein CM, et al. Role of inflammation and oxidative stress in atrial fibrillation. Heart Rhythm 2010; 7(4): 43844.
  • 11
    Singer DE, Chang Y, Fang MC, Borowsky LH, Pomernacki NK, Udaltsova N, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2(4): 297304.
  • 12
    Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22): 286470.
  • 13
    Karthikeyan G, Eikelboom JW. The CHADS2 score for stroke risk stratification in atrial fibrillation–friend or foe? Thromb Haemost 2010; 104(1): 458.
  • 14
    Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137(2): 26372.
  • 15
    Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31(19): 2369429.
  • 16
    Camm AJ, Lip GY, De CR, Savelieva I, Atar D, Hohnloser SH, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation – developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14(10): 1385413.
  • 17
    Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124.
  • 18
    Providencia R, Paiva L, Barra S. Risk stratification of patients with atrial fibrillation: biomarkers and other future perspectives. World J Cardiol 2012; 4(6): 195200.
  • 19
    Jover E, Roldan V, Gallego P, Hernandez-Romero D, Valdes M, Vicente V, et al. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed) 2012; 65(7): 62733.
  • 20
    Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive summary of a position document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] working group on thrombosis. Thromb Haemost 2011; 106(6): 9971011.
  • 21
    Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093100.
  • 22
    Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011; 57(2): 17380.
  • 23
    Gallego P, Roldan V, Torregrosa JM, Galvez J, Valdes M, Vicente V, et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5(2): 3128.
  • 24
    van Staa TP, Setakis E, Di Tanna GL, Lane DA, Lip GY. A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice. J Thromb Haemost 2011; 9(1): 3948.
  • 25
    Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51(8): 8105.
  • 26
    Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012; 125(13): 160516.
  • 27
    Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J 2013; 34(20): 147580.
  • 28
    Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation). J Am Coll Cardiol 2013; 61(22): 227484.
  • 29
    Roldán V, Marin F, Diaz J, Gallego P, Jover E, Romera M, et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost 2012; 10(8): 15007.
  • 30
    Zethelius B, Johnston N, Venge P. Troponin I as a predictor of coronary heart disease and mortality in 70-year-old men: a community-based cohort study. Circulation 2006; 113(8): 10718.
  • 31
    Omland T, de Lemos JA, Sabatine MS, Christophi CA, Rice MM, Jablonski KA, et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med 2009; 361(26): 253847.
  • 32
    Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108(7): 8338.
  • 33
    van den Bos EJ, Constantinescu AA, van Domburg RT, Akin S, Jordaens LJ, Kofflard MJ. Minor elevations in troponin I are associated with mortality and adverse cardiac events in patients with atrial fibrillation. Eur Heart J 2011; 32(5): 6117.
  • 34
    Wallentin L, Hijazi Z, Siegbahn A, Schollin M, Alexander JH, Atar D, et al. High sensitivity troponin-T for risk stratification in atrial fibrillation during treatment with apixaban or warfarin. Eur Heart J 2012; 33: (Abstract supplement 53).
  • 35
    Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50(25): 235768.
  • 36
    Asanin M, Stankovic S, Mrdovic I, Matic D, Savic L, Majkic-Singh N, et al. B-type natriuretic peptide predicts new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Peptides 2012; 35(1): 747.
  • 37
    Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009; 120(18): 176874.
  • 38
    Boos CJ, Anderson RA, Lip GY. Is atrial fibrillation an inflammatory disorder? Eur Heart J 2006; 27(2): 13649.
  • 39
    Devaraj S, Singh U, Jialal I. The evolving role of C-reactive protein in atherothrombosis. Clin Chem 2009; 55(2): 22938.
  • 40
    Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108(24):300610.
  • 41
    Lip GY, Patel JV, Hughes E, Hart RG. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007; 38(4): 122937.
  • 42
    Nyrnes A, Njolstad I, Mathiesen EB, Wilsgaard T, Hansen JB, Skjelbakken T, et al. Inflammatory biomarkers as risk factors for future atrial fibrillation. An eleven-year follow-up of 6315 men and women: the Tromso study. Gend Med 2012; 9(6): 53647.
  • 43
    Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. Am Heart J 2004; 148(3): 4626.
  • 44
    Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A. Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study). Am J Cardiol 2012; 109(1): 959.
  • 45
    Qu YC, Du YM, Wu SL, Chen QX, Wu HL, Zhou SF. Activated nuclear factor-kappaB and increased tumor necrosis factor-alpha in atrial tissue of atrial fibrillation. Scand Cardiovasc J 2009; 43(5): 2927.
  • 46
    Hak L, Mysliwska J, Wieckiewicz J, Szyndler K, Siebert J, Rogowski J. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interferon Cytokine Res 2009; 29(6): 32732.
  • 47
    Liuba I, Ahlmroth H, Jonasson L, Englund A, Jonsson A, Safstrom K, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace 2008; 10(7): 84853.
  • 48
    Marcus GM, Whooley MA, Glidden DV, Pawlikowska L, Zaroff JG, Olgin JE. Interleukin-6 and atrial fibrillation in patients with coronary artery disease: data from the Heart and Soul Study. Am Heart J 2008; 155(2): 3039.
  • 49
    Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol 2009; 104(1): 926.
  • 50
    Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115(1): 312.
  • 51
    Roldan V, Marin F, Blann AD, Garcia A, Marco P, Sogorb F, et al. Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. Eur Heart J 2003; 24(14): 137380.
  • 52
    Turgut N, Akdemir O, Turgut B, Demir M, Ekuklu G, Vural O, et al. Hypercoagulopathy in stroke patients with nonvalvular atrial fibrillation: hematologic and cardiologic investigations. Clin Appl Thromb Hemost 2006; 12(1): 1520.
  • 53
    Sakurai K, Hirai T, Nakagawa K, Kameyama T, Nozawa T, Asanoi H, et al. Left atrial appendage function and abnormal hypercoagulability in patients with atrial flutter. Chest 2003; 124(5): 16704.
  • 54
    Vene N, Mavri A, Kosmelj K, Stegnar M. High D-dimer levels predict cardiovascular events in patients with chronic atrial fibrillation during oral anticoagulant therapy. Thromb Haemost 2003; 90(6): 116372.
  • 55
    Nozawa T, Inoue H, Hirai T, Iwasa A, Okumura K, Lee JD, et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol 2006; 109(1): 5965.
  • 56
    Roldan V, Marin F, Muina B, Torregrosa JM, Hernandez-Romero D, Valdes M, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57(25): 2496504.
  • 57
    Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55(20): 222531.
  • 58
    Maehama T, Okura H, Imai K, Yamada R, Obase K, Saito K, et al. Usefulness of CHADS2 score to predict C-reactive protein, left atrial blood stasis, and prognosis in patients with nonrheumatic atrial fibrillation. Am J Cardiol 2010; 106(4): 5358.
  • 59
    Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, et al. Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 2007; 28(18): 221722.
  • 60
    Freestone B, Chong AY, Nuttall S, Blann AD, Lip GY. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 2007; 132(4): 12538.
  • 61
    Blann AD, Lip GY. The endothelium in atherothrombotic disease: assessment of function, mechanisms and clinical implications. Blood Coagul Fibrinolysis 1998; 9(4): 297306.
  • 62
    Conway DS, Pearce LA, Chin BS, Hart RG, Lip GY. Plasma von Willebrand factor and soluble p-selectin as indices of endothelial damage and platelet activation in 1321 patients with nonvalvular atrial fibrillation: relationship to stroke risk factors. Circulation 2002; 106(15): 19627.
  • 63
    Lip GY, Lane D, Van WC, Hart RG. Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation. Stroke 2006; 37(9): 2294300.
  • 64
    Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, et al. Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 2007; 27(12): 27638.
  • 65
    Choudhury A, Chung I, Blann AD, Lip GY. Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to P-selectin and antithrombotic therapy. Chest 2007; 131(3): 80915.
  • 66
    Kamath S, Chin BS, Blann AD, Lip GY. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul Fibrinolysis 2002; 13(7): 62736.
  • 67
    Chirinos JA, Castrellon A, Zambrano JP, Jimenez JJ, Jy W, Horstman LL, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm 2005; 2(5): 5259.
  • 68
    Heeringa J, Conway DS, van der Kuip DA, Hofman A, Breteler MM, Lip GY, et al. A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J Thromb Haemost 2006; 4(9): 19449.
  • 69
    Hayashi M, Takeshita K, Inden Y, Ishii H, Cheng XW, Yamamoto K, et al. Platelet activation and induction of tissue factor in acute and chronic atrial fibrillation: involvement of mononuclear cell-platelet interaction. Thromb Res 2011; 128(6): e1138.
  • 70
    Montoro-Garcia S, Shantsila E, Marin F, Blann A, Lip GY. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res Cardiol 2011; 106(6): 91123.
  • 71
    Rienstra M, Sun JX, Lubitz SA, Frankel DS, Vasan RS, Levy D, et al. Plasma resistin, adiponectin, and risk of incident atrial fibrillation: the Framingham Offspring Study. Am Heart J 2012; 163(1): 11924.
  • 72
    Filkova M, Haluzik M, Gay S, Senolt L. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol 2009; 133(2): 15770.
  • 73
    Karmazyn M, Purdham DM, Rajapurohitam V, Zeidan A. Signalling mechanisms underlying the metabolic and other effects of adipokines on the heart. Cardiovasc Res 2008; 79(2): 27986.
  • 74
    Shimano M, Shibata R, Tsuji Y, Kamiya H, Uchikawa T, Harata S, et al. Circulating adiponectin levels in patients with atrial fibrillation. Circ J 2008; 72(7): 11204.
  • 75
    Hernandez-Romero D, Jover E, Marin F, Vilchez JA, Manzano-Fernandez S, Romera M, et al. The prognostic role of the adiponectin levels in atrial fibrillation. Eur J Clin Invest 2013; 43(2): 16873.
  • 76
    Empana JP. Adiponectin isoforms and cardiovascular disease: the epidemiological evidence has just begun. Eur Heart J 2008; 29(10): 12213.
  • 77
    Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006; 6(10): 77283.
  • 78
    Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, Lip GY, et al. Subclinical atherosclerosis and risk of atrial fibrillation: the Rotterdam study. Arch Intern Med 2007; 167(4): 3827.
  • 79
    Nishizawa H, Shimomura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51(9): 273441.
  • 80
    Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, et al. Chronic kidney disease and prevalent atrial fibrillation: the chronic renal insufficiency cohort (CRIC). Am Heart J 2010; 159(6): 11027.
  • 81
    Iguchi Y, Kimura K, Kobayashi K, Aoki J, Terasawa Y, Sakai K, et al. Relation of atrial fibrillation to glomerular filtration rate. Am J Cardiol 2008; 102(8): 10569.
  • 82
    Go AS, Fang MC, Udaltsova N, Chang Y, Pomernacki NK, Borowsky L, et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119(10): 13639.
  • 83
    Roldan V, Marin F, Fernandez H, Manzano-Fernandez S, Gallego P, Valdes M, et al. Renal impairment in a “real-life” cohort of anticoagulated patients with atrial fibrillation (implications for thromboembolism and bleeding). Am J Cardiol 2013; 111(8): 115964.
  • 84
    Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J 2012; 33(22): 282130.
  • 85
    Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57(12): 133948.
  • 86
    Roldan V, Marin F, Manzano-Fernandez S, Fernandez H, Gallego P, Valdes M, et al. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013; 109(5): 95660.
  • 87
    Orenes-Pinero E, Manzano-Fernandez S, Lopez-Cuenca A, Marin F, Valdes M, Januzzi JL. Beta-trace protein: from GFR marker to cardiovascular risk predictor. Clin J Am Soc Nephrol 2013; 8(5): 87381.
  • 88
    Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002; 48(5): 699707.
  • 89
    Smith JG, Almgren P, Engstrom G, Hedblad B, Platonov PG, Newton-Cheh C, et al. Genetic polymorphisms for estimating risk of atrial fibrillation: a literature-based meta-analysis. J Intern Med 2012; 272(6): 57382.
  • 90
    Lopez-Cuenca A, Marin F, Roldan V, Gonzalez-Conejero R, Hernandez-Romero D, Valdes M, et al. Genetic polymorphisms and atrial fibrillation: insights into the prothrombotic state and thromboembolic risk. Ann Med 2010; 42(8): 56275.
  • 91
    Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 1999; 99(18): 24236.
  • 92
    Lip GY. Fibrinogen and cardiovascular disorders. QJM 1995; 88(3): 15565.
  • 93
    Yu Q, Safavi F, Roberts R, Marian AJ. A variant of beta fibrinogen is a genetic risk factor for coronary artery disease and myocardial infarction. J Investig Med 1996; 44(4): 1549.
  • 94
    Bozdemir V, Kirimli O, Akdeniz B, Ulgenalp A, Aslan A, Kala V, et al. The association of beta-fibrinogen 455 G/A gene polymorphism with left atrial thrombus and severe spontaneous echo contrast in atrial fibrillation. Anadolu Kardiyol Derg 2010; 10(3): 20915.
  • 95
    Marin F, Corral J, Roldan V, Gonzalez-Conejero R, del Rey ML, Sogorb F, et al. Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. J Mol Cell Cardiol 2004; 37(3): 699704.
  • 96
    Roldan V, Marin F, Gonzalez-Conejero R, Garcia-Honrubia A, Marti S, Alfaro A, et al. Factor VII -323 decanucleotide D/I polymorphism in atrial fibrillation: implications for the prothrombotic state and stroke risk. Ann Med 2008; 40(7): 5539.
  • 97
    Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the alpha2 gene in platelet GP Ia collagen receptor expression and function – effect in thromboembolic diseases. Thromb Haemost 1999; 81(6): 9516.
  • 98
    Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343(16): 113947.
  • 99
    Tello-Montoliu A, Marin F, Roldan V, Mainar L, Lopez MT, Sogorb F, et al. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med 2007; 262(6): 6518.